These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Evaluation of treatment satisfaction associated with the use of insulin aspart in continuous subcutaneous insulin infusion.
    Author: Wittlin SD, Marcus AO, Weng CS, Howard CP, Schorr AB, CONTROL Study Group.
    Journal: Diabetes Technol Ther; 2008 Feb; 10(1):1-10. PubMed ID: 18275357.
    Abstract:
    BACKGROUND: The purpose of this study was to compare treatment satisfaction among people with type 1 and type 2 diabetes after switching from insulin lispro to insulin aspart in continuous subcutaneous insulin infusion (CSII). Efficacy of glycemic control between treatments was also investigated. METHODS: Subjects using CSII with insulin lispro for 6 months or longer continued this therapy over a 4-week period and then switched to insulin aspart in CSII for 12 weeks. The Diabetes Treatment Satisfaction Questionnaire (DTSQ) and Insulin Treatment Satisfaction Questionnaire (ITSQ) were administered immediately prior to the switch and again at the end of 12 weeks of therapy with insulin aspart. Hemoglobin A(1c)(A1C) and fasting blood glucose (FBG) levels, insulin dose, and body weight were recorded at the same time points. RESULTS: Although average overall DTSQ score did not change significantly, average overall ITSQ score was significantly improved following the insulin aspart treatment. There was a small but statistically significant reduction in mean A1C and FBG following 12 weeks of CSII using insulin aspart. CONCLUSIONS: Both insulin aspart and insulin lispro are appropriate for CSII. ITSQ improvements suggest that aspects of CSII therapy with insulin aspart positively impact treatment satisfaction.
    [Abstract] [Full Text] [Related] [New Search]